Managers / Q4 2022 · view latest →
ISZO CAPITAL MANAGEMENT LP
CIK 0001607925 · 590 MADISON AVENUE, 21ST FLOOR, NEW YORK, NY, 10022 · 646-775-4394
Summary
Iszo Capital Management LP reported $7M in U.S.-listed holdings across 7 positions for Q4 2022.
The portfolio is heavily concentrated: LFCR alone accounts for 32.4% of reported value.
Compared with Q3 2022, the fund opened 2 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 64.7% · $5M
- REIT · 24.2% · $2M
- Other · 11.2% · $835,690
Quarter-over-Quarter Changes full breakdown →
vs Q3 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CVNACARVANA CO | NEW | +150.0K | 150.0K | +$711,000 | $711,000 |
| AMPYAMPLIFY ENERGY CORP NEW | NEW | +953 | 953 | +$8,377 | $8,377 |
| NAM TAI PPTY INC | SOLD OUT | −6.92M | 0 | −$29M | $0 |
| LNTHLANTHEUS HLDGS INC | TRIMMED | −119.2K | 17.1K | −$9M | $870,244 |
| LFCRLIFECORE BIOMEDICAL INC | TRIMMED | −1.16M | 373.8K | −$11M | $2M |
| CBLCBL & ASSOC PPTYS INC | TRIMMED | −54.0K | 78.3K | −$2M | $2M |
| CCELCRYO-CELL INTL INC | TRIMMED | −83.8K | 195.0K | −$876,019 | $824,981 |
| GLOBAL CORD BLOOD CORPORATIO | HELD | +0 | 279.5K | −$310 | $835,690 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | LFCRLIFECORE BIOMEDICAL INChistory → | COM | 32.38% | $2M | 373.8K |
| 2 | CBLCBL & ASSOC PPTYS INChistory → | COMMON STOCK | 24.17% | $2M | 78.3K |
| 3 | LNTHLANTHEUS HLDGS INChistory → | COM | 11.63% | $870,244 | 17.1K |
| 4 | GLOBAL CORD BLOOD CORPORATIO | SHS | 11.17% | $835,690 | 279.5K |
| 5 | CCELCRYO-CELL INTL INChistory → | COM | 11.03% | $824,981 | 195.0K |
| 6 | CVNACARVANA COhistory → | CL A | 9.51% | $711,000 | 150.0K |
| 7 | AMPYAMPLIFY ENERGY CORP NEW | COM | 0.11% | $8,377 | 953 |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2023 | $2M | 1 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $2M | 3 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $18M | 3 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $19M | 10 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $7M | 7 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $58M | 6 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $64M | 6 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $84M | 5 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $190M | 7 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $227M | 7 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $275M | 8 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $212M | 5 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $96M | 6 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $74M | 5 | Nov 17, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2020 | $57M | 10 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $65M | 10 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $69M | 3 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $76M | 4 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $64M | 2 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $61M | 5 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $92M | 5 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.